Comparative Pharmacology
Head-to-head clinical analysis: NITAZOXANIDE versus PYRIMETHAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITAZOXANIDE versus PYRIMETHAMINE.
NITAZOXANIDE vs PYRIMETHAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Interferes with pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reactions, essential for anaerobic metabolism in certain pathogens.
Pyrimethamine inhibits dihydrofolate reductase (DHFR) in the parasite, blocking the conversion of dihydrofolate to tetrahydrofolate, thereby inhibiting nucleic acid synthesis.
500 mg orally twice daily for 3 days for treatment of diarrhea caused by Cryptosporidium parvum or Giardia lamblia; for chronic giardiasis, 500 mg twice daily for 10 days.
For toxoplasmosis: 200 mg orally once, then 50-75 mg orally once daily for 4-6 weeks, plus sulfadiazine and folinic acid. For malaria prophylaxis: 25 mg orally once weekly.
None Documented
None Documented
Clinical Note
moderatePyrimethamine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pyrimethamine."
Clinical Note
moderatePyrimethamine + Artemether
"The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Artemether."
Clinical Note
moderatePyrimethamine + Lumefantrine
"The risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Lumefantrine."
Clinical Note
moderateThe terminal elimination half-life of the active metabolite tizoxanide is approximately 1.5–2 hours in adults and 2–4 hours in children. Clinical context: The short half-life supports twice-daily dosing; accumulation is minimal with normal dosing intervals.
Terminal elimination half-life is approximately 96 hours (range 80-123 hours) in adults with normal renal function; prolonged in renal impairment (up to 200 hours). This long half-life supports weekly dosing regimens.
Nitazoxanide is primarily excreted in feces (approximately 66%) and urine (approximately 33%). Renal elimination accounts for about 33% of the dose, primarily as the active metabolite tizoxanide (glucuronide conjugates), while fecal excretion accounts for approximately 66%, mostly as tizoxanide and its conjugates.
Primarily renal (approximately 30% unchanged and 20-30% as metabolites); additional biliary/fecal elimination (20-30% as metabolites). Total urinary excretion of parent drug and metabolites accounts for 60-80% of dose.
Category A/B
Category D/X
Antiprotozoal
Antimalarial / Antiprotozoal
Cyclophosphamide + Pyrimethamine
"The metabolism of Pyrimethamine can be decreased when combined with Cyclophosphamide."